SCHEMBL3090193

SCHEMBL3090193

Cc1ccc(NC(=O)NC2CCC(CCN3CCC(Oc4ccc(F)cc4Cl)CC3)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.48
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
EPHX2 P34913 7/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HTR1A P08908 1/20 0.46
HTR7 P34969 1/20 0.46
NPSR1 Q6W5P4 1/20 0.45
DRD3 P35462 4/20 0.45
DRD2 P14416 3/20 0.45
HTR2A P28223 3/20 0.44
UBE2M P61081 1/20 0.43
DCUN1D1 Q96GG9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3090192 1.00 RECQL (0.48) RECQLKDM4EALDH1A1EPHX2SMN1; SMN2
SCHEMBL3074537 0.93 EPHX2 (0.56) RECQLKDM4EALDH1A1EPHX2SMN1; SMN2
SCHEMBL3074535 0.93 EPHX2 (0.56) RECQLKDM4EALDH1A1EPHX2SMN1; SMN2
SCHEMBL27882701 0.88 HRH1 (0.47) DRD3HTR2A
SCHEMBL14715601 0.87 DRD3 (0.55) DRD3DRD2HTR2A
SCHEMBL3086334 0.87 DRD3 (0.55) DRD3DRD2HTR2A
SCHEMBL3093402 0.86 DRD2 (0.49) HTR1ADRD3DRD2HTR2A
SCHEMBL3079529 0.86 EPHX2 (0.60) RECQLEPHX2SMN1; SMN2MEN1KMT2A
Cyclopropane SCHEMBL14715571 0.86 NPC1 (0.48) DRD3DRD2HTR2A
SCHEMBL3079526 0.86 EPHX2 (0.60) RECQLEPHX2SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2079693-B1 ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS HOFFMANN LA ROCHE (CH) 2013-02-27 EP claimed
CN-101535258-B ether derivatives dual modulators of the 5HT2A and D3 receptors HOFFMANN LA ROCHE 2012-12-05 CN claimed
US-7795437-B2 Ether derivatives HOFFMANN-LA ROCHE INC. (US) 2010-09-14 US claimed
US-20080103174-A1 ETHER DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-05-01 US claimed
EP-2079693-B1 ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS HOFFMANN LA ROCHE (CH) 2013-02-27 EP disclosed
CN-101535258-B ether derivatives dual modulators of the 5HT2A and D3 receptors HOFFMANN LA ROCHE 2012-12-05 CN disclosed
US-7795437-B2 Ether derivatives HOFFMANN-LA ROCHE INC. (US) 2010-09-14 US disclosed
US-20080103174-A1 ETHER DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103174-A1 ETHER DERIVATIVES GABRE, BDNF, ADH1A RECQL 4130/4885KDM4E 573/4885ALDH1A1 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.